Bukwang announced that they decided to increase the patients of the second domestic clinical trial(CLV-203) of covid-19(SARS-CoV-2) treatment because they found the tendency of viruses' quantity reduction compared to placebo in the first domestic clinical trial(CLV-201). They explained that the analysis of CLV-201 has been still ongoing, so the final official data of it will come later.


The reason why they increased the number of patients in CLV-203 which measures the quantity of live viruses is to reinforce the reliability of the data.


40 patients which was the initial objective of CLV-203 were recruited just in 3 weeks and another added patients will be also recruited sooner.


It is expected that the anti-viral medicines as Levovir will be helpful to block the spread of viruses and prevent the patients' worsening condition due to COVID-19 by suppressing the live viruses.

Attachments

  • Permalink

Disclaimer

Bukwang Pharm. Co. Ltd. published this content on 19 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 April 2021 01:59:07 UTC.